Thymosin alpha-1 dosage calculator
Enter a vial and a dose and this returns the concentration, the volume and the syringe units. Underneath it, the same arithmetic worked out in advance for common vials, and the doses published studies of Thymosin alpha-1 actually used, every one quoted and cited. It converts numbers. It does not suggest what to take.
Work out concentration and what to draw
Two divisions, both shown. Concentration = mass in the vial ÷ diluent volume. Volume to draw = mass you want ÷ that concentration. Syringe units are that volume × the units per millilitre on your syringe's own scale.
Worked example: 5 mg in 2 mL is 2,500 mcg/mL, so 250 mcg is 0.1 mL, which is 10 units on a U-100 syringe and 4 units on a U-40. The scale is printed on the barrel; reading a U-40 syringe as if it were U-100 is a two-and-a-half-fold error.
Thymosin alpha-1 reconstitution chart
Units on a standard U-100 insulin syringe, where 100 units is 1 mL. The rows are the absolute doses quoted in studies of Thymosin alpha-1, from 1.6 mg to 3.2 mg, so this chart is specific to this compound rather than a generic ladder. More diluent means more units for the same dose, which is easier to measure accurately and empties the vial no faster.
| Dose | 1 mL diluent (2,000 mcg/mL) | 2 mL diluent (1,000 mcg/mL) | 3 mL diluent (667 mcg/mL) |
|---|---|---|---|
| 1.6 mg | 80 | 160 >1 mL | 240 >1 mL |
| 3.2 mg | 160 >1 mL | 320 >1 mL | 480 >1 mL |
| Dose | 1 mL diluent (5,000 mcg/mL) | 2 mL diluent (2,500 mcg/mL) | 3 mL diluent (1,667 mcg/mL) |
|---|---|---|---|
| 1.6 mg | 32 | 64 | 96 |
| 3.2 mg | 64 | 128 >1 mL | 192 >1 mL |
| Dose | 1 mL diluent (10,000 mcg/mL) | 2 mL diluent (5,000 mcg/mL) | 3 mL diluent (3,333 mcg/mL) |
|---|---|---|---|
| 1.6 mg | 16 | 32 | 48 |
| 3.2 mg | 32 | 64 | 96 |
Read a figure off this chart only if it matches the vial in front of you. A vial labelled a different strength, or reconstituted with a different volume, gives a different number for the same dose, and that is the single most common way these calculations go wrong.
Doses in published studies of Thymosin alpha-1
Each row is quoted from a paper in this compound's source ledger and carries the kind of evidence it came from. 5 of 6 come from human studies; the rest are animal or laboratory work.
| Evidence | Dose as the paper states it | Source |
|---|---|---|
| Human clinical trial | In TESTS, 1,106 septic adults received 1.6 mg thymosin alpha-1 or placebo subcutaneously every 12 hours for seven days. | pmid-39814420 |
| Human clinical trial | In the pancreatitis trial, 508 patients received 1.6 mg every 12 hours for seven days, then once daily for seven more. | pmid-35713670 |
| Human clinical trial | In chronic hepatitis B, 1.6 mg twice a week for six months was compared with interferon alpha. | pmid-17075991 |
| Human clinical trial | In severe acute pancreatitis, a pilot gave 3.2 mg twice a day for seven days. | pmid-20549321 |
| Human clinical trial | In colorectal cancer surgery, 1.6 mg twice a week (conventional) or three times a week (high dose) alongside chemotherapy. | pmid-37248723 |
| Animal, preclinical | Mice were protected from lethal Candida infection by 100 micrograms. | pmid-7085074 |
How long studies ran, and how far a vial goes
A vial lasts for a number of draws, not a number of weeks: divide the mass in the vial by the mass per draw and round down, which the vial planner does. How long that represents depends on frequency. For context, these are the durations studies of Thymosin alpha-1 actually ran for.
- Seven days of twice-daily injection in the sepsis phase 3, with 28-day mortality as the endpoint. pmid-39814420
- Fourteen days in the pancreatitis trial; six months in the hepatitis B trial; a median 38 months of follow-up in the cirrhosis trial. pmid-30063860
- Nine weeks of thymalfasin with three chemotherapy cycles before gastrectomy. pmid-41749205
How Thymosin alpha-1 was given
The route changes what a dose means. The same number given intravenously and subcutaneously is not the same exposure.
- Randomized controlled trial, humans, n=552, 2025: administration by subcutaneous route reported. A stratified block method was used for randomisation, and participants were stratified by age ( Interventions Subcutaneous injection of thymosin α1 or placebo every 12 hours for seven days unless discontinued owing to discharge from the… pmid-39814420
- Randomized controlled trial, humans, n=30, 2006: administration by subcutaneous route reported. The patients in group A received subcutaneous injection of 1.6 mg thymosin-alpha1, twice a week (T-alpha1 group) for six months, and the patients in group B received 5 MU interferon alpha (IFN-alpha) each day for fifteen days, then three… pmid-17075991
- Animal study, mice, 1982: administration by intravenous route reported. Two- to four-month-old mice were treated with graded doses of thymosin alpha 1 before, after, or before and after intravenous challenge with C. albicans. pmid-7085074
- In vitro study, 2025: administration by subcutaneous route reported. In this study, we thus aimed to exploit the potential of a liquid crystalline platform for the sustained release of peptide drug thymosin alpha 1 (Tα1), characterized by a short plasma half-life and with that associated twice-weekly SC administration regimen. pmid-40066714
Questions people ask
- How many units is 1.6 mg of Thymosin alpha-1?
- It depends entirely on how the vial was reconstituted. In a 5 mg vial with 2 mL of diluent it is 64 units on a U-100 syringe; with 1 mL it is 32. The chart above gives the rest.
- Does adding more diluent waste the peptide?
- No. The mass in the vial does not change. More diluent spreads the same mass through more liquid, so each dose is a larger, easier-to-measure volume and the vial yields exactly as many doses as before.
- Why does this page not recommend a dose?
- Because a dose is a clinical decision rather than a division. It depends on why someone is taking something, what else they take and how their kidneys and liver are working, none of which is knowable from a number typed into a box.
- Where do the doses in the table come from?
- Each is quoted from a specific paper indexed in Europe PMC, linked in the source column, and labelled with the kind of study it came from. The full evidence is on the Thymosin alpha-1 record.
What this calculator will not do
It will not take a body weight and return a milligram figure, and it will not tell you how often to draw. The table above is the published record, not a menu. A dose that appeared in a trial appeared under supervision, with monitoring, in people selected for that trial.
Other calculators
- Generic reconstitution calculatorThe same arithmetic, without a compound attached
- Unit convertermg, mcg, ng and syringe units
- Vial plannerDraws per vial and how long it lasts
- All compound calculatorsEvery compound with published dose figures